Breaking news

Concerns Rise Over Shareholder Movements At Bank Of Cyprus

Recent shareholder activities at the Bank of Cyprus have raised significant concerns within the financial community. At the Cyprus International Business Association Forum in Limassol, it was revealed that major stakeholders CarVal and Caius are contemplating the sale of their 14.65% stake in the bank. Bloomberg’s report on this potential divestiture has sparked a discourse on the future implications for the Cypriot banking sector, which is currently experiencing a period of robust health with strong capital reserves and liquidity.

The potential exit of CarVal and Caius brings to light the broader question of stability and the impact of foreign investment on local financial institutions. Industry experts, including analysts Dimitris Efstathiou and economist Fiona Mullen, have weighed in on the situation. Efstathiou noted that while the sector does not currently require additional capital injections, the entry of new foreign shareholders could catalyse technological innovation within the bank. Mullen echoed this sentiment, emphasizing the need for the banking system to maintain stability and to adapt to potential changes in shareholder dynamics.

The Bank of Cyprus, like many financial institutions in the region, has navigated through a tumultuous past, marked by economic crises and regulatory changes. The current high liquidity and capital levels are testament to its resilience and strategic management. However, the looming possibility of a major shareholder reshuffle introduces an element of uncertainty that could have far-reaching consequences for the bank’s operational and strategic directions.

The broader Cypriot banking sector could also feel the ripple effects of such a significant transaction. The introduction of new shareholders with different strategic priorities and visions could lead to shifts in business models, potentially affecting everything from customer service approaches to technological investments.

While the Cypriot banking sector enjoys a period of stability, the potential sale of a significant stake in the Bank of Cyprus by CarVal and Caius introduces an element of uncertainty. This development calls for careful monitoring and strategic planning to ensure the continued health and growth of the bank and the wider financial sector. The ability of the Bank of Cyprus to adapt to new ownership structures while maintaining its robust financial health will be crucial in navigating this period of change.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

eCredo
Aretilaw firm
The Future Forbes Realty Global Properties
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter